Biomx Inc represents a strong commitment to innovation, research, and breakthroughs in the field of microbiome therapeutics. The company's corporate philosophy is centered around developing personalized treatments to address unmet medical needs related to serious diseases and conditions caused by dysbiosis within the human microbiome. Biomx Inc strives to harness the power of the microbiome to improve patient outcomes and quality of life. Through cutting-edge technologies and strategic partnerships, Biomx Inc aims to advance the understanding and utilization of the microbiome, paving the way for innovative therapeutic solutions.

Biomx Inc is primarily present in the United States, with headquarters located in Ness Ziona, Israel.

Biomx Inc has achieved several significant milestones. The company has successfully developed a unique and innovative biotechnology platform that focuses on engineered phage products for the treatment of various diseases. Biomx Inc has also formed strategic partnerships with leading pharmaceutical companies, further enhancing their research and development capabilities. Notably, the company has advanced its clinical programs and successfully initiated Phase 1b/2a clinical studies, demonstrating promising results. Additionally, Biomx Inc has raised substantial funding through successful financing rounds, enabling them to support their cutting-edge research and reach key developmental targets. These achievements highlight Biomx Inc's commitment to advancing its novel therapeutic solutions and positioning itself as a key player in the biotechnology industry.

Biomx Inc is a biotechnology company specializing in the development of novel therapeutics using customized phage-based microbiome engineering. Founded in 2015, Biomx is dedicated to harnessing the power of the human microbiome to treat various diseases. With a focus on inflammatory bowel disease (IBD) and cancer, Biomx aims to revolutionize the field of microbiome-based therapeutics. Through their proprietary platform, Biomx engages in comprehensive research and development, leveraging cutting-edge technologies and scientific expertise. By understanding the intricate relationship between the human microbiome and diseases, Biomx is committed to delivering innovative, personalized therapies that have the potential to transform patient outcomes and improve lives.

The main competitors of Biomx Inc in the market include companies like Vedanta Biosciences, Seres Therapeutics, and Second Genome.

Biomx Inc is primarily active in the field of microbiome-based therapeutics.

Biomx Inc operates with a business model focused on the development of novel therapeutics using its proprietary microbiome-based technology platform. The company utilizes advanced computational tools and synthetic biology to identify and modify specific bacterial strains within the human microbiome, aiming to treat various diseases. By leveraging the potential of bacteria living within the body, Biomx Inc seeks to offer innovative solutions for conditions such as inflammatory bowel disease (IBD), cancer, and immuno-oncology. Through targeted modifications and interventions, Biomx Inc aims to harness the power of the microbiome to improve human health and address unmet medical needs.

Biomx hissesinin F/K oranı -12,90.

Biomx KUV 0 dir.

Biomx için AlleAktien Kalite Skoru 1/10'dur.

Biomx için şu an ciro hesaplanamıyor.

beklenen Biomx karı -4,20 Milyon. USD olarak gerçekleşmiştir.

The company Biomx Inc is a biotechnology company that specializes in the development and application of microbiome-related therapies. The various divisions of the company include research, development, and marketing of bacterial therapies and diagnostic tools for various diseases such as chronic inflammatory bowel disease, cancer, and skin diseases.

Biomx, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Biomx için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Biomx şirketinin ISIN kodu US09090D1037’dir.

Biomx 'nin WKN'si A2P9A0 'dir.

Biomx için Ticker PHGE’dir.

Son 12 ay içerisinde Biomx, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Biomx, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Biomx şirketinin mevcut temettü verimi .

Biomx dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Biomx, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Biomx, 'Sağlık' sektörüne atanmıştır.

Son Biomx tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 28.09.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 28.09.2024 olarak gerçekleşti.

2023 yılında Biomx tarafından 0 USD olarak temettüler dağıtıldı.

Biomx hisselerinin temettüleri USD olarak dağıtılır.